Uncategorized

Savara’s Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025. read more

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher. read more

Analyst sees Domino’s gaining share, Papa Johns steady, Pizza Hut slipping amid shifting dynamics in the pizza sector. read more

Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain. read more

Experts see China restrictions, Blackwell demand and guidance as the top items to watch for Nvidia’s Q1 financial results. Latest Ratings for NVDA Date Firm Action From To Mar 2022 Goldman Sachs Reinstates Neutral Feb 2022 Summit Insights Group Downgrades Buy Hold Feb 2022 Mizuho Maintains Buy View More Analyst Ratings for NVDA View the…

Organigram CEO Beena Goldenberg to retire after leading company to #1 in Canada and launching U.S. and global expansion plans. read more

Shares of CoreWeave, Inc. (NASDAQ: CRWV) are trading higher Tuesday following the company’s announcement of a key leadership appointment. read more

Germany became the world’s top importer of medical cannabis, but political pressure could challenge telehealth-driven growth. read more

Shares of GameStop Corp. (NYSE:GME) are trading higher Tuesday, continuing a recent uptrend that appears to be fueled by renewed interest from retail investors as well as upward momentum in Bitco read more

VOO, Vanguard’s S&P 500 ETF, is gaining popularity over its higher-cost counterpart SPY due to its lower expense ratio and optimal tax management. read more